- Home
- CNTA vs MATX Comparison
CNTA vs MATX Comparison
Compare CNTA & MATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | MATX |
|---|---|---|
| Founded | 2020 | 1882 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.4B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CNTA | MATX |
|---|---|---|
| Price | $39.62 | $183.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $43.17 | ★ $163.33 |
| AVG Volume (30 Days) | ★ 1.5M | 196.4K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | ★ 29.13 | N/A |
| EPS | N/A | ★ 1.85 |
| Revenue | $15,000,000.00 | ★ $3,344,500,000.00 |
| Revenue This Year | N/A | $4.65 |
| Revenue Next Year | N/A | $4.31 |
| P/E Ratio | ★ N/A | $97.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $86.97 |
| 52 Week High | $40.26 | $189.99 |
Technical Indicators
Market Signals| Indicator | CNTA | MATX |
|---|---|---|
| Relative Strength Index (RSI) | 71.86 | 60.46 |
| Support Level | $39.36 | $157.33 |
| Resistance Level | $39.86 | $189.99 |
| Average True Range (ATR) | 0.14 | 6.57 |
| MACD | -0.33 | -0.04 |
| Stochastic Oscillator | 50.50 | 79.20 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.